Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin -susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes[1].
Levonadifloxacin (32 μg/mL; 24 h) achieves a 90-99% intracellular reduction of MSSA and MRSA strains phagocytized in THP-1 monocytes with MICs of 0.03 μg/mL and 15.0 ng/mL[1].
Levonadifloxacin (12.5-400 mg/kg; s.c.; single dose) shows efficacy in vivo against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model[2].
| Animal Model: | Male/Female Swiss Albino mice (25-28 g) for plasma pharmacokinetic analyses[2] | ||||||||||||||||||||||||||||||||
| Dosage: | 12.5, 25, 50, 100, 200, 300 and 400 mg/kg | ||||||||||||||||||||||||||||||||
| Administration: | Subcutaneous injection; single dose; collected samples at 10 time points/dose (0.25, 0.5, 1, 2, 4, 6, 8, 10, 58 12 and 24 h post dose) | ||||||||||||||||||||||||||||||||
| Result: |
|
[1]. Dubois J, et al. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019 Dec;68(12):1716-1722.
[2]. Bhagwat SS, et al. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00909-19.